"Designing Growth Strategies is in our DNA"

Nuclear Medicines Radioisotopes Market Size, Share and Global Trend By Product Type (Diagnostics, Therapeutic), By Application (Oncology, Gastroenterology, Neurology, Orthopedics,Others), By End-user (Hospitals, Diagnostic centers, Specialty clinics, Education and research institutes, Others) and Geography Forecast till 2022-2029

Region : Global | Report ID: FBI101055 | Status : Ongoing



In June 2019, BGN Technologies Ltd. developed a novel method to produce molybdenum-99 and isotopes for medical imaging and nuclear medicine. Radioisotopes have become an integral part of the diagnostic procedures and help in the study of various dynamic processes taking place in the body. The short half-life of the radioisotopes and the ability to emit radiations make nuclear medicines radioisotopes apt to use in the treatment of diseases.

Nuclear medicines radioisotopes are extensively used for the diagnosis and treatment of almost all types of cancer. According to the World Health Organization, the total number of cancer cases in the world in 2018 are approximately 18.1 million which is estimated to reach 29.5 million by 2040, this could support the growth of the nuclear medicines radioisotopes market.

To gain extensive insights into the market, Request for Customization

Apart from this, radiopharmaceuticals are also employed to study the function of the various organs, examine the flow of blood to the brain and others. Nuclear medicines radioisotopes are now also being used for palliative care. For example, strontium-89 is used for the treatment of bone pain triggered by cancer.

The growth in global nuclear medicines radioisotopes market is being driven by the increase in demand for PET scan and nuclear medicines, deeper penetration of radioisotopes in healthcare and development of radiopharmaceuticals drugs. In addition, the huge government funding for the research in radioisotopes nuclear medicine is also anticipated to fuel the growth in global nuclear medicines radioisotopes market in the forecast years.

Conversely, strict government regulation and the risk of adverse effects due to increased exposure to radioisotopes are the major factors that can hamper the growth in global nuclear medicines radioisotopes market.

Key Players Covered

Some of the major companies that are present in the global nuclear medicines radioisotopes market Bayer AG, Medtronic plc, General Electric Company, Siemens Healthcare Private Limited, Cardinal Health, Aenorasis, Bracco Imaging S.p.A., Positron Corporation, Hologic Inc., and other players.




By Product Type

· Diagnostics

      - Technetium-99

      - Gallium-67

      - Thallium-201

      - Fluorine-18

      - Others

· Therapeutic

      - Rhenium-186

      - Iodine-131

      - Samarium-153

      - Yttrium-90

      - Others

By Application

· Oncology

· Gastroenterology

· Neurology

· Orthopedics

· Others

By End-user

· Hospitals

· Diagnostic centers

· Specialty clinics

· Education and research institutes

· Others

By Geography

· North America (USA and Canada)

· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

· Latin America (Brazil, Mexico and Rest of Latin America)

· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)


Currently, Technetium-99 is estimated to hold a major share of the global nuclear medicines radioisotopes market owing to its increasing adoption in diagnostics. According to the World Nuclear Organisation, nearly 40 million procedures are done per year using Technetium-99 accounting for almost 80% of the worldwide nuclear procedure.

Key Insights

  • Overview of regulatory scenario in key countries

  • Key mergers and acquisitions

  • Technological advancements in nuclear medicines radioisotopes market

Regional Analysis

The global nuclear medicines radioisotopes market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The nuclear medicines radioisotopes medicines market in North America is backed by active government support. According to the National Cancer Institute, in 2018, approximately 1,735,350 new cases of cancer are expected to be diagnosed in the United States, implying an increase in the nuclear medicines radioisotopes market in North America. The nuclear medicines radioisotopes market in Europe and the Asia Pacific is projected to expand in the forecast years due to the increase in the use of radioisotopes in the diagnosis of diseases and evolving health infrastructure.

Key Industry Developments

  • In February 2018, the U.S Food and Drug Administration and Nuclear Regulatory Commission (NRC) announced the approval of RadioGenix System, a system that produces Technetium-99m
  • In February 2019, the US Department of Energy’s National Nuclear Security Administration has chosen four companies to negotiate agreement regarding the supply of molybdenum-99.
  • In October 2018, Novartis AG announced the acquisition of Endocyte which would also include 177Lu-PSMA-617, a radio ligand candidate for treatment of prostrate cancer.

  • Ongoing
  • 2021
  • 2018-2020


  • $4850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients


Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.